RHO and melanoma: In this study, we demonstrate that the combination of a Rho/MRTF pathway inhibitor, CCG-222740, and the MEK inhibitor trametinib synergistically inhibits the viability of a subset of NRAS mutant melanoma cells and induced apoptosis in melanoma lines with a highly activated Rho/MRTF pathway.